K.N. Mahesh Prasad v. Optimus Drugs Private Limited
Case brief
What is this about?
Commercial Court Appeal; temporary injunction refused; Consultancy and Shareholders' Agreement dated 03.11.2018; Call Option Notice dated 22.08.2023; transfer of 3,90,245 equity shares (2% paid-up capital); Optimus Drugs Private Limited; Optrix Laboratories; promoter and managing director; Sekhmet Pharma majority acquisition; termination of agreement unchallenged; compensation clause linked to scope of services; specific performance suit C.O.S.No.2 of 2024; earlier suit C.O.S.No.32 of 2022 and abandoned first Call Option Notice (I.A.No.383 of 2023); prima facie case, balance of convenience, irreparable loss; abandonment under Order XXIII Rule 1(a) CPC and Order II Rule 2 CPC left open; readiness and willingness under Section 16(c) Specific Relief Act left open; interim orders vacated; appeals dismissed without costs.
What did the court decide?
None; COMCA Nos.18 and 19 of 2025 and all connected applications dismissed, interim orders if any stand vacated, no order as to costs